Cebrian-Bonesana A, Schvartzman E, Roca-Garcia C, Pependieck C, Sackmann-Muriel S, Ojeda F G, Kvicala R, Pavlovsky S, Lein J M, Penchansky L
Cancer. 1978 Jun;41(6):2372-8. doi: 10.1002/1097-0142(197806)41:6<2372::aid-cncr2820410641>3.0.co;2-y.
One hundred twenty two children with non-Hodgkin's lymphoma were studied from January 1966 to December 1975. The first group (1966-1972) did not receive an uniform treatment. The second group (1973-1975) entered in a G.A.T.L.A. protocol consisting of: vincristine-prednisone plus surgery and/or radiotherapy as induction treatment, craniocervical radiotherapy and intrathecal methotrexate as CNS preventive treatment and anti-leukemia (6-mercaptopurine, methotrexate and vincristine-prednisone pulses) or anti-lymphoma (COPP) treatment as maintenance, in a randomized trial. Comparison of survival of the two groups are as follows: series 1966-1972, 22% and 20% at 12 and 24 months of evolution, respectively, and series 1973-1975, 33% and 26% at 12 and 24 months, respectively. After 2 years of complete remission we have not seen any relapse. We conclude that 1) this disease is highly malignant and must be treated with more intensive chemotherapeutic treatment, and 2) there is no difference between antileukemia or anti-lymphoma maintenance treatment, as yet.
1966年1月至1975年12月期间,对122名非霍奇金淋巴瘤患儿进行了研究。第一组(1966 - 1972年)未接受统一治疗。第二组(1973 - 1975年)进入了一项儿童肿瘤研究协作组(G.A.T.L.A.)方案,该方案包括:长春新碱 - 泼尼松加手术和/或放疗作为诱导治疗,颅颈放疗和鞘内注射甲氨蝶呤作为中枢神经系统预防性治疗,以及抗白血病(6 - 巯基嘌呤、甲氨蝶呤和长春新碱 - 泼尼松脉冲疗法)或抗淋巴瘤(COPP)治疗作为维持治疗,这是一项随机试验。两组生存率比较如下:1966 - 1972年组,病程12个月和24个月时的生存率分别为22%和20%;1973 - 1975年组,病程12个月和24个月时的生存率分别为33%和26%。完全缓解2年后未观察到任何复发。我们得出结论:1)这种疾病恶性程度高,必须采用更强化的化疗进行治疗;2)目前抗白血病或抗淋巴瘤维持治疗之间没有差异。